Top 10 Medical Stocks To Invest In Right Now

Thesis: The threat to enforce federal marijuana laws might backfire by pushing Congress to legalize marijuana on the federal level. While in the short term, marijuana related stocks might suffer, if legislation is passed and signed into law, it would not only ease fears, but also make it more likely that more states will follow along with the pot legalization trend. This will have a long term positive effect on marijuana stocks.

The Threat

Right now, even though it flies in the face of reality and evidence, marijuana is listed as a schedule one drug: a drug with high potential for abuse, no currently accepted medical treatment use in the U.S., and lack of accepted safety for use of the drug or substance under medical supervision.

President Trump has threatened to increase enforcement of federal cannabis laws. One might think that this will have a negative impact on marijuana and marijuana related stocks like Aurora Cannabis (OTCQB:ACBFF), General Cannabis (OTCQB:CANN), Americann (OTCQX:ACAN), and MassRoots (OTCQB:MSRT), and if implemented it probably would be devastating, both to publicly traded marijuana companies, and to local companies in regions that have legalized pot.

Top 10 Medical Stocks To Invest In Right Now: iShares Mortgage Real Estate Capped (REM)

Advisors’ Opinion:

  • [By Donald van Deventer]

    The latest implied forward rate forecast from Kamakura Corporation shows projected 10-year U.S. Treasury yields differing -0.07% to 0.03% from last week while fixed rate mortgage yields varied by -0.01% to 0.08%. Mortgage yields, determined by the Monday through Wednesday weekly survey of the Federal Home Loan Mortgage Corporation, lag Treasury movements simply because of the 3-day yield calculation used in the Primary Mortgage Market Survey. The 10-year U.S. Treasury yield is projected to rise from 2.92% at Thursday’s close (down 0.06% from last week) to 3.374% (down 0.06% from last week) in one year. The 10-year U.S. Treasury yield in ten years is forecast to reach 4.639%, 1 basis point lower than last week. The 15-year fixed rate mortgage rate is forecast to rise from the effective yield of 3.69% on Thursday (down 0.001% from last week) to 4.222% (down 0.006% from last week) in one year and 6.29% in 10 years, up 0.038% from last week. We explain the background for these calculations in the rest of this note, along with some mortgage servicing rights metrics. The forecast allows investors in exchange traded U.S. Treasury funds (TLT) (TBT), total return bond funds (BOND), municipal bonds (NUV) and exchange traded mortgage funds (REM) to assess likely total returns over the next 120 months. Treasury-related exchange traded funds affected by the forward rates include:

Top 10 Medical Stocks To Invest In Right Now: Callon Petroleum Company(CPE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday’s regular session.

Top 10 Medical Stocks To Invest In Right Now: Bayer Aktiengesellschaft (BAYRY)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    This type of spin-off is not uncommon among German companies, as they streamline their portfolios to focus on the where they have more competitive advantages in the long term. For instance, in the recent past, Siemens (OTCPK:SIEGY) has split out Osram (OTC:OSAGY) and Bayer (OTCPK:BAYRY) has performed the spin-off of Covestro (OTCPK:CVXTY), something that Rheinmetall is likely to do in the near future because its auto unit has reached peak margins, and therefore this is the best time to spin-off the business.

  • [By SEEKINGALPHA.COM]

    The Regeneron press release in November for its Q3 2017 financial and operating results reaffirmed Eylea’s full year 2017 U.S. net product sales growth of approximately 10% over 2016, which could be about $1 billion. From our model, we see the Q4 total revenues for Eylea, excluding sales outside the United States from Regeneron’s collaborative partner Bayer AG (OTCPK:BAYRY), of $1.2 billion, or a 17% increase year-on-year. REGN stock has a forward P/E ratio of 21.83 as of December 8, 2017, while the current trailing P/E is 34.57.

  • [By SEEKINGALPHA.COM]

    Fertilizers are only one input when it comes to farming, the equipment business has suffered, and seed suppliers are certainly concerned. Perhaps that is why another merger occurred last week between Monsanto (NYSE:MON) and Bayer (OTCPK:BAYRY). Bayer AG agreed to buy the U.S. seed manufacturer for $128 per share or approximately $47 billion creating a mammoth company with a combined value of almost $134.5 billion. The $128 per share price works out to a valuation of around 16 times earnings, which is cheap in a market where the average of S&P 500 stocks is trading at over 26.5 times earnings. However, the weakness in the agricultural sector caused disappointing earnings for Monsanto in the third quarter and a downbeat outlook for the future caused MON to accept Bayer’s bid. Bayer bought Monsanto at a low price, lowering the risk of the transaction for the German health care and agricultural giant.

  • [By Todd Campbell]

    Nektar Therapeutics is working with Bayer AG (NASDAQOTH:BAYRY) on an inhaledversion of Amikacin, an anti-bacterial that if successful in trials could be used alongside standard of care to treat gram-negative pneumonia in intubated and mechanically ventilated patients. If it’s eventually approved in the U.S., Nektar Therapeutics will receive a flat 30% royalty on sales. It’s also working with Bayer on an inhaled powder formulation of Cipro that could be used to treat chronic lung infections in cystic fibrosis patients. Top-line phase 3 results on both drugs should be available this year.

  • [By SEEKINGALPHA.COM]

    As the graphic below shows, ImmunoGen’s product pipeline is potentially significant. Furthermore, it is impressive to see the involvement and partnerships in these early stage compounds by some of the world’s leading pharmaceutical and biotech companies. This includes firms like Amgen (NASDAQ:AMGN), Roche (OTCQX:RHHBY), Bayer (OTCPK:BAYRY), Sanofi (NYSE:SNY), Eli Lilly (NYSE:LLY), and Novartis (NYSE:NVS).

Top 10 Medical Stocks To Invest In Right Now: WPP plc(WPPGY)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    WPP plc (WPPGY) — Most of WPP’s public websites were rendered inaccessible after the world’s biggest advertising group said its IT systems were the focus of a suspected cyberattack. Shares traded down almost 1% in early afternoon.

Top 10 Medical Stocks To Invest In Right Now: Entercom Communications Corporation(ETM)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap radio broadcasting stock Entercom Communications Corp (NYSE: ETM), a potential peer of Emmis Communications Corporation (NASDAQ: EMMS), Saga Communications (NYSEAMERICAN: SGA) and troubled Cumulus Media (NASDAQ: CMLS), is the tenth most shorted stock on the NYSE with short interest of 45.06% according to Highshortnterest.com.

Top 10 Medical Stocks To Invest In Right Now: GlaxoSmithKline PLC(GSK)

Advisors’ Opinion:

  • [By Todd Campbell]

    Also, like in hepatitis C, competitors are attempting to win away market share. For example,ViiV Healthcare, a joint venture spearheaded by GlaxoSmithKline(NYSE:GSK), is actively pursuing new HIV therapies that could make it more difficult for Gilead Sciences to maintain its market share dominance. In December, ViiV announced that a single tablet, two-drug combination that includes Johnson & Johnson’s Edurant met its primary endpoint in phase 3 studies. A filing for FDA approval is slated for this year.

  • [By WWW.MONEYSHOW.COM]

    Donald Trump understands how regulation harms both businesses and consumers, discouraging innovation and raising costs. In a recent news conference, he pledged to “cut regulations by 75%, maybe more.”  This is good news indeed for drug companies like GlaxoSmithKline (GSK).

  • [By Paul Ausick]

    GlaxoSmithKline plc (NYSE: GSK) dropped about 1% Wednesday to post a new 52-week low of $34.52 after closing at $34.86 on Tuesday. The stock’s 52-week high is $44.54. Volume of around 4.8 million was about equal to the daily average. The company’s HIV drug is being challenged by a potentially better drug from competitor Gilead Sciences.

  • [By Keith Speights]

    Gilead’s primary rival in the HIV market is Viiv Healthcare, which is majority-owned byGlaxoSmithKline (NYSE:GSK).The company recently announced positive results from a late-stage clinical study of its HIV drug Tivicay combined with Johnson & Johnson’s Edurant.

  • [By Sean Williams]

    Third, in late March, Mylan announced that the Food and Drug Administration had rejected its application to market a generic version of GlaxoSmithKline’s (NYSE:GSK) blockbuster asthma and COPD inhalable drug, Advair. GlaxoSmithKline’s Advair lost patent protection more than six years ago, but only within the past couple of years did the FDA lay out a course for generic drug producers to follow in order to get a generic version of the drug approved. Meanwhile, Glaxo still enjoys blockbuster sales of Advair as generic versions of the drug have yet to hit the market.

Top 10 Medical Stocks To Invest In Right Now: Royal Gold Inc.(RGLD)

Advisors’ Opinion:

  • [By Scott Levine]

    Climbing nearly 6% through January, the price of gold outpaced the meager gain — approximately 1% — of the S&P 500. Unsurprisingly, many of the market’s largest gold stocks enjoyed double-digit gains, including AngloGold Ashanti (NYSE:AU), Barrick Gold (NYSE:ABX), IAMGOLD (NYSE:IAG), and Royal Gold (NASDAQ:RGLD).

  • [By Alex McGuire]

    This list ranks gold dividend stocks in the mining sector by dividend yield. And it also includes one of our top gold stock recommendations of 2017…

    Gold Dividend Stock Share Price Year-to-Date Performance Dividend Yield (as of June 30)
    DRDGOLD Ltd. (NYSE ADR: DRD) $3.19 -39.7% 10.24%
    Sibanye Gold Ltd. (NYSE ADR: SBGL) $4.70 -33.4% 5.98%
    Harmony Gold Mining Co. (NYSE ADR: HMY) $1.62 -26.7% 4.56%
    Gold Fields Limited (NYSE ADR: GFI) $3.41 +13.3% 2.73%
    Randgold Resources Ltd. (Nasdaq ADR: GOLD) $87.68 +14.9% 1.89%
    Franco Nevada Corp. (NYSE: FNV) $72.39 +21.1% 1.27%
    Royal Gold Inc. (Nasdaq: RGLD) $76.85 +21.3% 1.25%
    Eldorado Gold Corp. (NYSE: EGO) $2.58 -19.9% 1.16%
    Barrick Gold Corp. (NYSE: ABX) $15.90 -0.5% 0.75%
    Goldcorp Inc. (NYSE: GG) $13.02 -4.4% 0.62%

    Six of the 10 gold stocks listed above have posted negative returns so far in 2017. The main reason behind their losses has to do with gold price volatility.

Top 10 Medical Stocks To Invest In Right Now: Chesapeake Utilities Corporation(CPK)

Advisors’ Opinion:

  • [By Lisa Levin]

    On Tuesday, utilities shares slipped by just 0.5 percent. Meanwhile, top gainers in the sector included Pampa Energia S.A. (ADR) (NYSE: PAM), up 2 percent, and Chesapeake Utilities Corporation (NYSE: CPK) up 3 percent.

Top 10 Medical Stocks To Invest In Right Now: BanColombia S.A.(CIB)

Advisors’ Opinion:

  • [By Matt Smith]

    Bancolombia appears attractively priced
    Another Colombian company that appears under-valued is the Andean country’s largest commercial bank Bancolombia (NYSE: CIB  ) . For the year-to-date Bancolombia’s share price fell 17% because of a weak second quarter bottom-line. This decline was primarily caused by the bank’s net income plunging by 41% year-over-year because of mark-to-market losses caused by the value lost in the bank’s securities portfolio.

  • [By Javier Hasse]

    Analysts at Credit Suisse downgraded shares of Bancolombia SA (ADR) (NYSE: CIB) from Outperform to Neutral, while boosting their price target from $38 to $40.

  • [By Lisa Levin]

    Foreign Regional Banks: This industry declined 2 percent by 11:00 am with Bancolombia SA (ADR) (NYSE: CIB) moving down 3.7 percent. Bancolombia’s PEG ratio is 4.51.

Top 10 Medical Stocks To Invest In Right Now: Hudson Pacific Properties, Inc.(HPP)

Advisors’ Opinion:

  • [By Lisa Levin]

    Here is the list of stocks going ex-dividend on Friday.

    Douglas Dynamics Inc (NYSE: PLOW) – $0.2350 dividend, 2.9183 percent yield
    Tiffany & Co. (NYSE: TIF) – $0.4500 dividend, 2.6758 percent yield
    PulteGroup, Inc. (NYSE: PHM) – $0.0900 dividend, 1.7078 percent yield
    Leidos Holdings, Inc. (NYSE: LDOS) – $0.3200 dividend, 3.0851 percent yield
    Tupperware Brands Corporation (NYSE: TUP) – $0.6800 dividend, 4.1756 percent yield
    Hudson Pacific Properties Inc (NYSE: HPP) – $0.2000 dividend, 2.36

Leave a Reply

Your email address will not be published. Required fields are marked *